Considering the key roles of aromatase and ERs on ER+ breast tumors, the anti-cancer drugs with dual AI and SERM properties are pointed as a future therapeutic strategy for ER+ breast cancer treatment [22]. This evidence concerns the gene CYP19A1 and cancer.